{6 (nirmatrelvir 150 MG Oral Tablet) / 5 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 3... — RxCUI 2704987
RxNorm drug concept · Brand name pack
RxCUI 2704987
Brand name pack · BPCK
● Current RxNorm concept 6 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2704987
Official name{6 (nirmatrelvir 150 MG Oral Tablet) / 5 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 300 MG /100 MG ; 150 MG / 100 MG Dose Pack]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asPaxlovid 300 MG / 100 MG ; 150 MG / 100 MG Dose Pack; PAXLOVID 300 MG ; 100 MG (Day 1), 150 MG ; 100 MG (Days 2-5) Dose Pack
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)151,858 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ritonavir: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Ritonavir must always be used with other HIV medicines — that's how it's approved and how it works best. HIV treatment is a combination approach because using just one drug gives t...
- Why do I have to take ritonavir with other HIV medicines — can't I just take it alone?
- Yes, stomach side effects are actually the most common complaint with ritonavir — things like nausea, diarrhea, vomiting, and stomach pain are reported by a large number of people...
- I'm getting a lot of nausea and diarrhea. Is that normal, and will it get better?
🕸️ Concept Web — How {6 (nirmatrelvir 150 MG Oral Tablet) / 5 (ritona... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
{6 (nirmatrelvir 150 MG Oral Tablet) / 5 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 300 MG /100 MG ; 150 MG / 100 MG Dose Pack]
RxCUI 2704987 Brand name pack · BPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Nirmatrelvir
2587892IN -
Ritonavir
85762IN
-
Nirmatrelvir
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Nirmatrelvir Oral Tablet
2587896SCDF -
Ritonavir Oral Tablet
900574SCDF -
Nirmatrelvir Oral Product
2587894SCDG -
Nirmatrelvir Pill
2587895SCDG -
Ritonavir Oral Product
1165486SCDG -
Ritonavir Pill
1165487SCDG -
Pack
746839DF -
Oral Product
1151131DFG - +1 more in this family
-
Nirmatrelvir Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Nirmatrelvir 150 MG Oral Tablet
2587897SCD -
Ritonavir 100 MG Oral Tablet
900575SCD -
Nirmatrelvir 150 MG
2587893SCDC -
Ritonavir 100 MG
317488SCDC
-
Nirmatrelvir 150 MG Oral Tablet
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Nirmatrelvir 150 MG Oral Tablet
SCD · 2587897 -
Ritonavir 100 MG Oral Tablet
SCD · 900575 -
{6 (nirmatrelvir 150 MG Oral Tablet) / 5 (ritonavir 100 MG Oral Tablet) } Pack
GPCK · 2704986 -
Nirmatrelvir 150 MG
SCDC · 2587893 -
Ritonavir 100 MG
SCDC · 317488 -
Nirmatrelvir Oral Tablet
SCDF · 2587896 -
Ritonavir Oral Tablet
SCDF · 900574 -
Nirmatrelvir Oral Product
SCDG · 2587894 -
Nirmatrelvir Pill
SCDG · 2587895 -
Ritonavir Oral Product
SCDG · 1165486
📦 FDA Products & Package NDCs
6 products · 6 package NDCs
6 package NDCs map to RxCUI 2704987 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00069-0521-11 | 1 BLISTER PACK in 1 CARTON (0069-0521-11) / 1 KIT in 1 BLIS... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2025-04-15 |
| 00069-5045-30 | 10 BLISTER PACK in 1 CARTON (0069-5045-30) / 1 KIT in 1 BLI... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2025-07-09 |
| 00069-5317-20 | 10 BLISTER PACK in 1 CARTON (0069-5317-20) / 1 KIT in 1 BLI... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2023-10-18 |
| 00069-5321-30 | 10 BLISTER PACK in 1 CARTON (0069-5321-30) / 1 KIT in 1 BLI... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2023-10-18 |
| 00069-5434-20 | 10 BLISTER PACK in 1 CARTON (0069-5434-20) / 1 KIT in 1 BLI... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2025-07-09 |
| 00069-5450-11 | 1 BLISTER PACK in 1 CARTON (0069-5450-11) / 1 KIT in 1 BLIS... | Paxlovid | Pfizer Laboratories Div Pfizer Inc | 2026-01-05 |
Observed labelers:
Pfizer Laboratories Div Pfizer Inc (6)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.